The effects of the glutamate u-amino-3hydroxy 5-methyl-4-isoxazole propionate (AMPA) recep tor antagonist L Y -293558 in reducing ischemic brain dam age have been assessed in halothane-anesthetized cats. Focal cerebral ischemia was produced by permanent oc clusion of one middle cerebral artery, and the animals were killed 6 h later. The amount of early irreversible ischemic damage was assessed at 16 predetermined ste reotactic planes by an observer blinded to treatment par adigm employed. Treatment with LY-293558 (15 mg/kg i. v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral artery occlusion reduced significantly (p The marked elevation in extracellular concentra tion of glutamate in cerebral ischemia is putatively a key factor in the sequence of cellular events that results in ischemic damage to neurons (Choi, 1992) .
< 0.02) the volume of ischemic damage (from 3,423 ± 212 mm 3 of the cerebral hemisphere in vehicle-treated cats to 2,822 ± 569 mm 3 in LY-293558-treated cats). The present data demonstrate that an AMP A receptor antagonist can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period. These data provide additional support for the clinical evaluation of AMP A receptor antagonists in focal cere bral ischemia in humans. Key Words: Glutamate Cerebral ischemia-Cerebrovascular disease.
The advent of selective antagonists for the a-amino-3-hydroxy 5-methyl-4-isoxazole propio nate (AMPA) receptor subtype has allowed assess ment of the role of this receptor in the genesis of ischemic damage. In global ischemia in rodents, there have been convincing demonstrations that AMP A receptor antagonists reduce ischemic injury to the striatum, cortex, and hippocampus (Shear down et aI., 1990; Buchan et aI., 1991; Nellgard and Wieloch, 1992; Diemer et aI., 1992; Le Peillet et aI., 1992) . The anti-ischemic efficacy of AMPA recep tor antagonists in global ischemia contrasts with the limited and controversial efficacy of NMDA antag onists in the same global models (see McCulloch et aI., 1991; Nellgard and Wieloch, 1992) . In focal ce rebral ischemia in the rat, AMPA receptor antago nists have been reported to reduce the volume of infarction (Buchan et aI., 1991a; Gill et aI., 1992; Smith and Meldrum, 1992) though no coherent view has emerged of the relative neuroprotective po tency of this pharmacological class in relation to that of NMDA antagonists (for comparisons see Buchan et aI., 1991b; Gill et aI., 1991) .
In the present study we have examined the ef fects of the novel AMP A receptor antagonist L Y-293558 (Ornstein et aI., 1993 ) in a gyrencephalic model of focal cerebral ischemia that we have shown previously to be highly effective in demon strating the anti-ischemic effects of competitive and noncompetitive NMDA receptor antagonists (Ozyurt et aI., 1988; Park et aI., 1988; Bullock et aI., 1990; Chen et aI., 1991) .
METHODS
The investigations were carried out in 15 adult cats weighing between 2.2 and 3.0 kg. The cat was anesthe tized (Saffan, 9 mg/kg, i.v. total steroids), intubated, and connected to a positive pressure ventilator delivering ni trous oxide and oxygen in an open circuit. Polyethylene catheters were inserted into one femoral vein and one femoral artery for the administration of drugs and the continuous monitoring of arterial blood pressure, respec tively. Anesthesia was maintained throughout the course of the investigation with a nitrous oxide/oxygen mixture (70%:30%) containing 1-1.5% halothane. Throughout the experimental period, MABP was maintained constant at -80 mm Hg by increasing the inclination of the hind limbs and/or i.v. infusion of Hartman's Solution (up to -100 ml/cat). The arterial hematocrit was assessed at intervals throughout the experiment to determine the extent of any hemodilution. In one cat, the criterion MABP (80 mm Hg) could not be achieved prior to drug administration or after treatment with LY-293558; in this animal MABP re mained 40-50 mm Hg throughout. No measurements of lesion size were made in this animal.
Normocapnia (Paco2 close to 32 mm Hg) was main tained by adjusting the stroke volume of the respirator. Metabolic acidosis was corrected by administration of so dium bicarbonate (8.4%). Regular samples of arterial blood were taken for the determination of respiratory sta tus using a direct reading electrode system (Corning). The animals were maintained normothermic using a heating blanket with feedback control via a rectal thermistor probe. A thermistor probe also was inserted periosteally, overlying the parietal cortex, via a scalp incision ipsilat eral to the middle cerebral artery to be occluded.
The left middle cerebral artery (MCA) was occluded via a transorbital approach by a neurosurgeon experi enced in the procedure. The head of the cat was placed in a stereotactic frame. With microsurgical techniques, the left orbit was exenterated and the posterolateral orbital wall was removed with a dental drill to expose the dura mater overlying the MCA. Under the operating micro scope the dura was incised and the MCA exposed along its course from its origin to the bifurcation. A detailed drawing of the anatomy of the MCA was made in all animals. The trunk of the MCA, all collateral vessels and all visible branches of the lenticulostriate arteries were coagulated with a bipolar diathermy and the MCA trunk divided with microscissors.
L Y -293558 (I5 mg/kg) dissolved in isotonic saline was administered as a slow (3 min) i. v. injection, 30 min be fore the occlusion of the MCA. A constant i. v. infusion of L Y -293558 (7 mg/kg/h) was initiated immediately after the loading bolus and maintained thereafter until sacrifice. Control animals received a bolus injection of isotonic sa line (10 mllkg i. v.) 30 min prior to MCA occlusion. An i.v. infusion of saline (0.15 mllmin i. v.) was initiated immedi-ately thereafter and maintained until sacrifice. In all ani mals, samples of arterial blood were withdrawn at hourly intervals and centrifuged, and plasma levels of the drug determined by high performance liquid chromatography.
Six hours after the occlusion of the MCA, the cat was sacrificed by transcardiac perfusion fixation with F AM (40% formaldehyde, glacial acetic acid, and methanol in a ratio 1: 1: 8). Briefly, the cat was placed in a supine posi tion and heparinized. A thoracotomy was performed and a cannula introduced into the ascending aorta via the left ventricle. Physiological saline (-250 m!) was infused, at a pressure equivalent to the MABP, for 20 s. This was fol lowed immediately by 1.5 L of F AM fixative at the same pressure. After perfusion the cat was decapitated and the head was stored in the same fixative at 4°C for at least 12 h. The brain was then removed. After marking the left side of the forebrain with India ink, the hindbrain was detached by a cut through the midbrain and the cerebral hemispheres were cut into five equally spaced coronal slices. These slices were embedded in paraffin wax and sections 7-8-f,Lm thick were cut at 200-f,Lm intervals throughout the specimens (-150-200 sections from each forebrain). The sections were stained by hemalum and eosin and by a method combining cresyl violet and Luxol fast blue. Those sections that corresponded most closely to 16 stereotactically predetermined coronal planes of cat brain from the atlas of Reinoso-Suarez (1961) were exam ined by conventional light microscopy without prior knowledge of the animal's history. Any abnormalities were charted on the diagrams (Fig. 1) . The area of isch emic damage in the cerebral hemisphere, cerebral cortex, and caudate nucleus was determined from the diagrams, at each of the 16 coronal planes (Fig. 1) , using a com puter-based image-analysis system (Cambridge Instru ments Quantimet 970). The volumes of ischemic damage were calculated from the areas of damage at the different coronal planes and their antero-posterior coordinates.
Statistical analysis
Data are presented as mean ± SD. For cardiovascular, respiratory, and other systemic variables, statistical com parison between the two experimental groups was per formed with two-tailed Student's t test. The volumes of ischemic damage in the two experimental groups were compared with a one-tailed Student's t test because of the a priori decision to examine only the ability of the drug to reduce the volume of ischemic damage. The area of isch emic damage at each coronal plane was compared be tween the two groups by two-tailed Student's t test be cause of the possibility of bidirectional changes even when the volume is reduced.
RESULTS

Systemic variables
During the postocclusion survival period, there were no significant differences between vehicle treated and LY-293558-treated cats in respect of arterial pressure (Fig. 2) , rectal temperature, and periosteal temperature (Fig. 3) . In vehicle-treated cats, at the time of MCA occlusion, arterial oarbon dioxide tension was 30.4 ± 0.8 mm Hg, arterial ox ygen tension was 168 ± 26 mm Hg, and hematocrit 30 ± 7%; there were no significant changes in these drug levels of 37.6 ± 14.6 fLg/ml at 60 min after MCA occlusion. There was no significant deviation from this level over the course of the succeeding 5 h (Fig. 4) .
DISCUSSION
The advent of selective AMPA antagonists [such as 2 ,3-dihydroxy-6-nitro-7 -sulfamoyl-benzo- The quinoxalinedione NBQX has been the most ex tensively investigated AMPA antagonist in cerebral ischemia (Sheardown et aI., 1990; Buchan et aI., 1991a,b; Diemer et aI., 1992; Nellgard and Wieloch, 1992; Gill et aI., 1992) but the low solubility of NBQX in aqueous media and its limited and poorly defined penetration of the blood-brain barrier and concern over its precipitation in renal tubules may restrict its experimental and clinical utility. The benzodiazepine GYKI 52466 has attracted increas ing attention (Le Peillet et aI., 1992; Smith and Mel drum, 1992) as an AMPA antagonist although its precise site of interaction with the AMPA receptor ionophore remains to be definitely identified. The recently described decahydroisoquinoline carbox ylic acid (LY-293558) and its racemate LY-215490 are potent, systemically active AMPA antagonists with therapeutic potential that are readily soluble in aqueous media (Ornstein et aI., 1993) . fLmollkg (Ornstein et aI., 1993) .
The present report describing that the AMP A an tagonist L Y -293558 significantly reduces the amount of ischemic damage in a cat model of focal cerebral ischemia confirms previous work with other AMP A antagonists and contributes several new aspects. The present study provides definitive evidence that AMP A receptor antagonists are neu roprotective in focal ischemia in a gyrencephalic species. This is a particularly important observation as the potent anti-ischemic effects of NBQX in global ischemia in rodents (Sheardown et aI., 1990; Buchan et aI., 1991; Diemer et aI., 1992; Nellgard and Wieloch, 1992) have not been readily demon strable in a canine model of global ischemia (Lanier et aI., 1993) . The present data provide evidence that the ben efit conveyed by AMP A antagonists in focal cere bral ischemia cannot be attributed to artifactual or drug-induced alterations in key physiological vari ables (such as MABP or temperature). The impor tance of monitoring and controlling physiological variables in studies of neuroprotective drugs is in creasingly recognized (Ginsberg and Busto, 1989) .
In the majority of investigations (particularly those with outcome assessed 24 h or more after the in sult), monitoring is restricted to the surgical and immediate postoperative period (Buchan et aI., 1991; Gill et aI., 1992) . The demonstration that hy pothermia initiated 3 h after the onset of ischemia markedly reduces ischemic damage in focal isch emia in the rat when assessed at 24 h emphasizes the importance of temperature changes beyond the immediate peri-ischemic period (Xue et aI., 1992) .
In the present study arterial pressure and tempera ture were continuously monitored throughout the entire period of ischemia and were not different in the vehicle-treated and LY-293558-treated cats. (Smith and Meldrum, 1992) , the benefits of NBQX in focal ischemia were more modest (Buchan et aI., 1991b; Gill et aI., 1992) . The reductions in lesion size with NBQX were similar to or smaller than that with NMDA antagonists in the hands of the same investigators (Gill et aI., 1991; Buchan et aI., 1992) . In the cat, in the present study, the volume of tissue salvaged with the AMPA antagonist LY-293558 (600 mm 3 ) was smaller than that noted with competitive and non competitive NMDA antagonists (1,300 and 1,600 mm 3 , respectively) but similar to that salvaged with polyamine site-NMDA antagonists (750-800 mm 3 )
and kappa receptor agonists that act putatively to reduce glutamate release (776 mm 3 ) (Ozyurt et aI., 1988; Gotti et aI., 1988; Bullock et aI., 1990; Mackay et aI., 1993) . Caution must be exercised in comparing data from different studies because of subtle but potentially important differences in ex perimental design (e.g., anesthesia, surgery, sur vival period). It should be recognized that for LY-293558 (as well as for NBQX and GYKI 52466) much less attention has been focused upon optimiz ing dosing regimen than for NMDA receptor antag onists (see Gotti et aI., 1988; Gill et aI., 1991; Chen et aI., 1991 , for precise definition of dose depen dency of the response to NMDA antagonists).
In conclusion, the present report provides evi dence that an AMPA antagonist (LY-293558) with therapeutic potential reduces ischemic damage in a cat model of focal ischemia in which key physiolog ical variables have been assessed throughout the postischemic period, thus adding to the evidence that AMPA antagonists offer an additional ap proach to NMDA antagonists for modification of ischemic brain injury.
